相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。β-Lactam antimicrobials: what have you done for me lately?
George H. Talbot
ANTIMICROBIAL THERAPEUTICS REVIEWS: THE BACTERIAL CELL WALL AS AN ANTIMICROBIAL TARGET (2013)
Activity of Ceftaroline-Avibactam Tested against Gram-Negative Organism Populations, including Strains Expressing One or More β-Lactamases and Methicillin-Resistant Staphylococcus aureus Carrying Various Staphylococcal Cassette Chromosome mec Types
Mariana Castanheira et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
In Vitro Activity of MK-7655, a Novel β-Lactamase Inhibitor, in Combination with Imipenem against Carbapenem-Resistant Gram-Negative Bacteria
Elizabeth B. Hirsch et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
In Vitro Antibacterial Activity of the Ceftazidime-Avibactam (NXL104) Combination against Pseudomonas aeruginosa Clinical Isolates
Premavathy Levasseur et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Target- and Resistance-Based Mechanistic Studies with TP-434, a Novel Fluorocycline Antibiotic
Trudy H. Grossman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Can We Really Use ß-Lactam/ß-Lactam Inhibitor Combinations for the Treatment of Infections Caused by Extended-Spectrum ß-Lactamase-Producing Bacteria?
Federico Perez et al.
CLINICAL INFECTIOUS DISEASES (2012)
Progress on Developing Endpoints for Registrational Clinical Trials of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infections: Update From the Biomarkers Consortium of the Foundation for the National Institutes of Health
George H. Talbot et al.
CLINICAL INFECTIOUS DISEASES (2012)
White Paper: Recommendations on the Conduct of Superiority and Organism-Specific Clinical Trials of Antibacterial Agents for the Treatment of Infections Caused by Drug-Resistant Bacterial Pathogens
Brad Spellberg et al.
CLINICAL INFECTIOUS DISEASES (2012)
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance
A. -P. Magiorakos et al.
CLINICAL MICROBIOLOGY AND INFECTION (2012)
Policy Statement on Antimicrobial Stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS)
Neil Fishman et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2012)
In vitro activity of the siderophore monosulfactam BAL30072 against meropenem-non-susceptible Acinetobacter baumannii
Paul G. Higgins et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
200 NEJM ANNIVERSARY ARTICLE The Perpetual Challenge of Infectious Diseases
Anthony S. Fauci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
ESBLs: A Clear and Present Danger?
Rishi H. -P. Dhillon et al.
CRITICAL CARE RESEARCH AND PRACTICE (2012)
Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-Producing Enterobacteriaceae
David M. Livermore et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Evaluation of Ceftazidime and NXL104 in Two Murine Models of Infection Due to KPC-Producing Klebsiella pneumoniae
Andrea Endimiani et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Activity of ACHN-490 Tested Alone and in Combination with Other Agents against Pseudomonas aeruginosa
Glenn A. Pankuch et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
In Vitro Activity of Ceftazidime-NXL104 against 396 Strains of β-Lactamase-Producing Anaerobes
Diane M. Citron et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
In Vivo Efficacy of a Human-Simulated Regimen of Ceftaroline Combined with NXL104 against Extended-Spectrum-β-Lactamase (ESBL)-Producing and Non-ESBL-Producing Enterobacteriaceae
Dora E. Wiskirchen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
In Vitro Activity of Ceftazidime Combined with NXL104 versus Pseudomonas aeruginosa Isolates Obtained from Patients in Canadian Hospitals (CANWARD 2009 Study)
A. Walkty et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Activity of NXL104 in Combination with β-Lactams against Genetically Characterized Escherichia coli and Klebsiella pneumoniae Isolates Producing Class A Extended-Spectrum β-Lactamases and Class C β-Lactamases
P. R. S. Lagace-Wiens et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
New antimicrobial agents on the horizon
Karen Bush et al.
BIOCHEMICAL PHARMACOLOGY (2011)
Combating Antimicrobial Resistance: Policy Recommendations to Save Lives
Robert J. Guidos et al.
CLINICAL INFECTIOUS DISEASES (2011)
In vitro activity of BAL30072 against Burkholderia pseudomallei
Takehiko Mima et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2011)
Antibiotics in the clinical pipeline in 2011
Mark S. Butler et al.
JOURNAL OF ANTIBIOTICS (2011)
In vivo and in vitro activity of the siderophore monosulfactam BAL30072 against Acinetobacter baumannii
Thomas A. Russo et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Updated Functional Classification of beta-Lactamases
Karen Bush et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
In Vitro Properties of BAL30072, a Novel Siderophore Sulfactam with Activity against Multiresistant Gram-Negative Bacilli
Malcolm G. P. Page et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
The 10 x '20 Initiative: Pursuing a Global Commitment to Develop 10 New Antibacterial Drugs by 2020
David N. Gilbert et al.
CLINICAL INFECTIOUS DISEASES (2010)
Recommended Design Features of Future Clinical Trials of Antibacterial Agents for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
Brad Spellberg et al.
CLINICAL INFECTIOUS DISEASES (2010)
The future of the beta-lactams
Leticia I. Llarrull et al.
CURRENT OPINION IN MICROBIOLOGY (2010)
Combating evolution with intelligent design: the neoglycoside ACHN-490
Eliana S. Armstrong et al.
CURRENT OPINION IN MICROBIOLOGY (2010)
New beta-lactam antibiotics and beta-lactamase inhibitors
Karen Bush et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2010)
Multidrug Resistance among Gram-Negative Pathogens That Caused Healthcare-Associated Infections Reported to the National Healthcare Safety Network, 2006-2008
Alexander J. Kallen et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2010)
Activity of the siderophore monobactam BAL30072 against multiresistant non-fermenters
Shazad Mushtaq et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters
Shazad Mushtaq et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Helen W. Boucher et al.
CLINICAL INFECTIOUS DISEASES (2009)
Antibiotic-Resistant Bugs in the 21st Century -- A Clinical Super-Challenge.
Cesar A. Arias et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The epidemic of antibiotic-resistant infections: A call to action for the medical community from the Infectious Diseases Society of America
Brad Spellberg et al.
CLINICAL INFECTIOUS DISEASES (2008)
Federal funding for the study of antimicrobial resistance in nosocomial pathogens: No ESKAPE
Louis B. Rice
JOURNAL OF INFECTIOUS DISEASES (2008)
Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship
Timothy H. Dellit et al.
CLINICAL INFECTIOUS DISEASES (2007)
Trends in antimicrobial drug development: Implications for the future
B Spellberg et al.
CLINICAL INFECTIOUS DISEASES (2004)
分享论文
